{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:31:27Z","timestamp":1776083487931,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1038\/nrd773","type":"journal-article","created":{"date-parts":[[2002,9,20]],"date-time":"2002-09-20T19:52:51Z","timestamp":1032551571000},"page":"309-315","source":"Crossref","is-referenced-by-count":1910,"title":["Protein kinases \u2014 the major drug targets of the twenty-first century?"],"prefix":"10.1038","volume":"1","author":[{"given":"Philip","family":"Cohen","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"BFnrd773_CR1","doi-asserted-by":"crossref","unstructured":"Cohen, P. The origins of protein phosphorylation. Nature Cell Biol. (in the press).","DOI":"10.1038\/ncb0502-e127"},{"key":"BFnrd773_CR2","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1073\/pnas.75.4.2021","volume":"75","author":"MS Collett","year":"1978","unstructured":"Collett, M. S. & Erikson, R. L. Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl Acad. Sci. USA 75, 2021\u20132024 (1978).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd773_CR3","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1016\/S0021-9258(18)34459-4","volume":"257","author":"M Castagna","year":"1982","unstructured":"Castagna, M. et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumour-promoting phorbol esters. J. Biol. Chem. 257, 7847\u20137851 (1982).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR4","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0021-9258(19)85886-6","volume":"255","author":"A Kishimoto","year":"1980","unstructured":"Kishimoto, A., Takai, Y., Mori, T., Kikkawa, U. & Nishizuka, Y. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J. Biol. Chem. 255, 2273\u20132276 (1980).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR5","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.1021\/bi00316a032","volume":"23","author":"H Hidaka","year":"1984","unstructured":"Hidaka, H., Inagaki, M., Kawamoto, S. & Sasaki, Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23, 5036\u20135041 (1984).","journal-title":"Biochemistry"},{"key":"BFnrd773_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3171\/jns.1992.76.4.0571","volume":"76","author":"M Shibuya","year":"1992","unstructured":"Shibuya, M. et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid haemorrhage. J. Neurosurg. 76, 571\u2013577 (1992).","journal-title":"J. Neurosurg."},{"key":"BFnrd773_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1527-3466.1998.tb00346.x","volume":"16","author":"T Asano","year":"1998","unstructured":"Asano, T., Ikegaki, I., Satoh, S., Seto, M. & Sasaki, Y. A protein kinase inhibitor, fasudil (AT-877); a novel approach to signal transduction therapy. Cardiovascular Drug Rev. 16, 76\u201387 (1998).","journal-title":"Cardiovascular Drug Rev."},{"key":"BFnrd773_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1042\/bj3510095","volume":"351","author":"SP Davies","year":"2000","unstructured":"Davies, S. P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351, 95\u2013105 (2000).","journal-title":"Biochem. J."},{"key":"BFnrd773_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1126\/science.273.5272.245","volume":"273","author":"K Kimura","year":"1996","unstructured":"Kimura K. et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245\u2013248 (1996).","journal-title":"Science"},{"key":"BFnrd773_CR10","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/40187","volume":"389","author":"M Uehata","year":"1997","unstructured":"Uehata, M. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990\u2013994 (1997).","journal-title":"Nature"},{"key":"BFnrd773_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0006-291X(86)90008-2","volume":"135","author":"T Tamaoki","year":"1986","unstructured":"Tamaoki, T. et al. Staurosporine, a potent inhibitor of phospholipid\/Ca2+ dependent protein kinase. Biochem. Biophys. Res. Commun. 135, 397\u2013402 (1986).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrd773_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0014-5793(89)81494-2","volume":"259","author":"PD Davis","year":"1992","unstructured":"Davis, P. D. et al. Potent selective inhibitors of protein kinase C. FEBS Lett. 259, 61\u201363 (1992).","journal-title":"FEBS Lett."},{"key":"BFnrd773_CR13","doi-asserted-by":"crossref","first-page":"15771","DOI":"10.1016\/S0021-9258(18)98476-0","volume":"266","author":"D Toullec","year":"1991","unstructured":"Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 15771\u201315781 (1991).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0014-5793(96)01510-4","volume":"402","author":"DR Alessi","year":"1997","unstructured":"Alessi, D. R. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP-K1\u03b2 (Rsk-2) and p70 S6 kinase. FEBS Lett. 402, 121\u2013123 (1997).","journal-title":"FEBS Lett."},{"key":"BFnrd773_CR15","doi-asserted-by":"publisher","first-page":"5600","DOI":"10.1074\/jbc.275.8.5600","volume":"275","author":"PR Graves","year":"2000","unstructured":"Graves, P. R. et al. The CHK1 protein kinase and the CDC25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 275, 5600\u20135605 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR16","first-page":"17","volume":"15","author":"D Fabbro","year":"2000","unstructured":"Fabbro, D. et al. PKC412, a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Res. 15, 17\u201328 (2000).","journal-title":"Anticancer Drug Res."},{"key":"BFnrd773_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0378-5173(00)00350-1","volume":"198","author":"GL Engel","year":"2000","unstructured":"Engel, G. L., Farid, N. A., Faul, M. M., Richardson, L. A. & Winneroski, L. L. Salt form selection and characterisation of LY 333531 mesylate monohydrate. Int. J. Pharm. 198, 239\u2013247 (2000).","journal-title":"Int. J. Pharm."},{"key":"BFnrd773_CR18","doi-asserted-by":"publisher","first-page":"25302","DOI":"10.1074\/jbc.M011601200","volume":"276","author":"AC Maroney","year":"2001","unstructured":"Maroney, A. C. et al. CEP-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 276, 25302\u201325308 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.1862342","volume":"253","author":"DR Knighton","year":"1991","unstructured":"Knighton, D. R. et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407\u2013414 (1991).","journal-title":"Science"},{"key":"BFnrd773_CR20","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu, J. et al. Calcineurin is a common target of cyclophilin\u2013cyclosporin A and FKBP\u2013 FK506 complexes. Cell 66, 807\u2013815 (1991).","journal-title":"Cell"},{"key":"BFnrd773_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0014-5793(82)80319-0","volume":"137","author":"AA Stewart","year":"1982","unstructured":"Stewart, A. A., Ingebritsen, T. S., Manalan, A., Klee, C. B. & Cohen, P. Discovery of a Ca2+ and calmodulin-dependent protein phosphatase: probable identity with calcineurin (CaM-BP80). FEBS Lett. 137, 80\u201384 (1982).","journal-title":"FEBS Lett."},{"key":"BFnrd773_CR22","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/jnci\/93.20.1517","volume":"93","author":"K Garber","year":"2001","unstructured":"Garber, K. Rapamycin's resurrection: a new way to target the cancer cell cycle. J. Natl Cancer Inst. 93, 1517\u20131519 (2001).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrd773_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1677\/erc.0.0080249","volume":"8","author":"K Yu","year":"2001","unstructured":"Yu, K. et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8, 249\u2013258 (2001).","journal-title":"Endocr. Relat. Cancer"},{"key":"BFnrd773_CR24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.1715094","volume":"253","author":"J Heitman","year":"1991","unstructured":"Heitman, J. Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253, 905\u2013909 (1991).","journal-title":"Science"},{"key":"BFnrd773_CR25","doi-asserted-by":"publisher","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumours to inhibition of FRAP\/mTOR. Proc. Natl Acad. Sci. USA 98, 10314\u201310319 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd773_CR26","doi-asserted-by":"publisher","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina, K. et al. An inhibitor of mTOR reduces neoplasia and normalises p70\/S6 kinase activity in Pten+\/\u2212 mice. Proc. Natl Acad. Sci. USA 98, 10320\u201310325 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd773_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6468(08)70091-2","volume":"38","author":"JL Adams","year":"2001","unstructured":"Adams, J. L., Badger, A. M., Kumar, S. & Lee, J. C. p38 MAP kinase: molecular target for the inhibition of proinflammatory cytokines. Prog. Med. Chem. 38, 1\u201360 (2001).","journal-title":"Prog. Med. Chem."},{"key":"BFnrd773_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/0192-0561(88)90007-0","volume":"10","author":"JC Lee","year":"1988","unstructured":"Lee, J. C., Griswold, D. E., Votta, B. & Hanna, N. Inhibition of monocyte IL-1 production by the anti-inflammatory compound SK&F 86002. Int. J. Immunopharmacol. 10, 835\u2013843 (1988).","journal-title":"Int. J. Immunopharmacol."},{"key":"BFnrd773_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/372739a0","volume":"372","author":"JC Lee","year":"1994","unstructured":"Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739\u2013746 (1994).","journal-title":"Nature"},{"key":"BFnrd773_CR30","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1126\/science.7914033","volume":"265","author":"J Han","year":"1994","unstructured":"Han, J., Lee, J. D., Bibbs, L. & Ulevitch R. J. A MAP kinase targetted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808\u2013811 (1994).","journal-title":"Science"},{"key":"BFnrd773_CR31","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0092-8674(94)90277-1","volume":"78","author":"J Rouse","year":"1994","unstructured":"Rouse, J. et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027\u20131037 (1994).","journal-title":"Cell"},{"key":"BFnrd773_CR32","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/0092-8674(94)90278-X","volume":"78","author":"NW Freshney","year":"1994","unstructured":"Freshney, N. W. et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039\u20131049 (1994).","journal-title":"Cell"},{"key":"BFnrd773_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0014-5793(95)00357-F","volume":"364","author":"A Cuenda","year":"1995","unstructured":"Cuenda, A. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 364, 229\u2013233 (1995).","journal-title":"FEBS Lett."},{"key":"BFnrd773_CR34","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nsb0497-311","volume":"4","author":"L Tong","year":"1997","unstructured":"Tong, L. et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Struct. Biol. 4, 311\u2013316 (1997).","journal-title":"Nature Struct. Biol."},{"key":"BFnrd773_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1074-5521(98)90170-3","volume":"5","author":"PA Eyers","year":"1998","unstructured":"Eyers, P. A., Craxton, M., Morrice, N., Cohen, P. & Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem. Biol. 5, 321\u2013328 (1998).","journal-title":"Chem. Biol."},{"key":"BFnrd773_CR36","doi-asserted-by":"publisher","first-page":"15605","DOI":"10.1074\/jbc.273.25.15605","volume":"273","author":"RJ Gum","year":"1998","unstructured":"Gum, R. J. et al. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP-binding pocket. J. Biol. Chem. 273, 15605\u201315610 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR37","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1126\/science.276.5314.955","volume":"276","author":"M Mohammadi","year":"1997","unstructured":"Mohammadi, M. et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276, 955\u2013960 (1997).","journal-title":"Science"},{"key":"BFnrd773_CR38","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1432-1033.1997.0518a.x","volume":"243","author":"WF De Azevedo","year":"1997","unstructured":"De Azevedo, W. F. et al. Inhibition of cyclin-dependent protein kinases by purine analogues: crystal structure of human Cdk2 complexed with roscovitine. Eur. J. Biochem. 243, 518\u2013526 (1997).","journal-title":"Eur. J. Biochem."},{"key":"BFnrd773_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.281.5376.533","volume":"281","author":"NS Gray","year":"1998","unstructured":"Gray, N. S. et al. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science 281, 533\u2013538 (1998).","journal-title":"Science"},{"key":"BFnrd773_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/0006-2952(94)90042-6","volume":"48","author":"WH Ward","year":"1994","unstructured":"Ward, W. H. et al. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48, 659\u2013666 (1994).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrd773_CR41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1126\/science.8066447","volume":"265","author":"DW Fry","year":"1994","unstructured":"Fry, D. W. et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093\u20131095 (1994).","journal-title":"Science"},{"key":"BFnrd773_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1432-1033.1994.1047b.x","volume":"225","author":"N Osherov","year":"1994","unstructured":"Osherov, N. & Levitski, A. Epidermal-growth-factor-dependent activation of the src-family kinases. Eur. J. Biochem. 225, 1047\u20131053 (1994).","journal-title":"Eur. J. Biochem."},{"key":"BFnrd773_CR43","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1038\/sj.onc.1204102","volume":"19","author":"MJ Morin","year":"2000","unstructured":"Morin, M. J. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19, 6574\u20136583 (2000).","journal-title":"Oncogene"},{"key":"BFnrd773_CR44","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.1038\/sj.onc.1204085","volume":"19","author":"AM Senderowicz","year":"2000","unstructured":"Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19, 6600\u20136606 (2000).","journal-title":"Oncogene"},{"key":"BFnrd773_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/9035","volume":"1","author":"R Hoessel","year":"1999","unstructured":"Hoessel, R. et al. Indirubin, the active constituent of a chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1, 60\u201367 (1999).","journal-title":"Nature Cell Biol."},{"key":"BFnrd773_CR46","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100\u2013104 (1996).","journal-title":"Cancer Res."},{"key":"BFnrd773_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells. Nature Med. 2, 561\u2013566 (1996).","journal-title":"Nature Med."},{"key":"BFnrd773_CR48","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd773_CR49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI9083","volume":"105","author":"BJ Druker","year":"2000","unstructured":"Druker, B. J. & Lydon, N. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia. J. Clin. Invest. 105, 3\u20137 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnrd773_CR50","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler, T. et al. Structural mechanism of STI-571 inhibition of Abelson tyrosine kinase. Science 289, 1938\u20131942 (2000).","journal-title":"Science"},{"key":"BFnrd773_CR51","first-page":"139","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor, STI-571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors. J. Pharmacol. Exp. Ther. 295, 139\u2013145 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd773_CR52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","volume":"344","author":"H Joensuu","year":"2001","unstructured":"Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052\u20131056 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd773_CR53","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1073\/pnas.92.17.7686","volume":"92","author":"DT Dudley","year":"1995","unstructured":"Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J. & Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92, 7686\u20137689 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd773_CR54","doi-asserted-by":"publisher","first-page":"27489","DOI":"10.1074\/jbc.270.46.27489","volume":"270","author":"DR Alessi","year":"1995","unstructured":"Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T. & Saltiel, A. R. PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489\u201327494 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR55","doi-asserted-by":"publisher","first-page":"18623","DOI":"10.1074\/jbc.273.29.18623","volume":"273","author":"MF Favata","year":"1998","unstructured":"Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623\u201318632 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrd773_CR56","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/10533","volume":"5","author":"JS Sebolt-Leopold","year":"1999","unstructured":"Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810\u2013816 (1999).","journal-title":"Nature Med."},{"key":"BFnrd773_CR57","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/377441a0","volume":"377","author":"EJ Brown","year":"1995","unstructured":"Brown, E. J. et al. Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature 377, 441\u2013446 (1995).","journal-title":"Nature"},{"key":"BFnrd773_CR58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0014-5793(99)00552-9","volume":"451","author":"PA Eyers","year":"1999","unstructured":"Eyers, P. A., van den Ijssel, P., Quinlan, R. A., Goedert, M. & Cohen, P. Use of a drug-resistant mutant of stress-activated protein kinase 2a\/p38 to validate the in vivo specificity of SB 203580 FEBS Lett. 451, 191\u2013196 (1999).","journal-title":"FEBS Lett"},{"key":"BFnrd773_CR59","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification. Science 293, 876\u2013880 (2001).","journal-title":"Science"},{"key":"BFnrd773_CR60","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","volume":"7","author":"S Frame","year":"2001","unstructured":"Frame, S., Cohen, P. & Biondi, R. M. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321\u20131327 (2001).","journal-title":"Mol. Cell"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd773","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrd773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrd773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:28:46Z","timestamp":1684466926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["BFnrd773"],"URL":"https:\/\/doi.org\/10.1038\/nrd773","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}